Ivonescimab Cuts Death Risk 27% vs Pembrolizumab in NSCLC Trial

Ivonescimab demonstrated a 27% reduction in death risk compared to pembrolizumab in a Phase III trial for PD-L1-positive advanced non-small cell lung cancer, with a stronger effect in high PD-L1 expression patients and a safety profile that may expand treatment to squamous histology patients.

This Wire brief sits within Fusion42's coverage of Biotech.